CDK12 and prostate carcinoma: While CDK12 inactivation results in focal tandem duplications in the genome of prostate cancer cells and generates a large number of neoantigens, which could make patients of this subtype ideal candidates for immunotherapy, further clinical testing is needed to determine the efficacy of this treatment.19